stoxline Quote Chart Rank Option Currency Glossary
  
PMV Pharmaceuticals, Inc. (PMVP)
1.61  0.03 (1.9%)    07-23 16:00
Open: 1.57
High: 1.63
Volume: 126,423
  
Pre. Close: 1.58
Low: 1.55
Market Cap: 83(M)
Technical analysis
2024-07-23 4:54:33 PM
Short term     
Mid term     
Targets 6-month :  2.02 1-year :  2.36
Resists First :  1.73 Second :  2.02
Pivot price 1.56
Supports First :  1.55 Second :  1.45
MAs MA(5) :  1.59 MA(20) :  1.58
MA(100) :  1.75 MA(250) :  2.97
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  47.6 D(3) :  47.2
RSI RSI(14): 48.4
52-week High :  9.72 Low :  1.17
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PMVP ] has closed below upper band by 30.1%. Bollinger Bands are 41.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.63 - 1.64 1.64 - 1.65
Low: 1.53 - 1.54 1.54 - 1.55
Close: 1.6 - 1.61 1.61 - 1.62
Company Description

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

Headline News

Mon, 22 Jul 2024
Mirae Asset Global Investments Co. Ltd. Acquires Shares of 15,492 PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World

Mon, 01 Jul 2024
A look into PMV Pharmaceuticals Inc (PMVP)’s deeper side - SETE News

Thu, 09 May 2024
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights - GlobeNewswire

Sat, 20 Apr 2024
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth - Simply Wall St

Sat, 13 Apr 2024
PMVP Stock Price and Chart — NASDAQ:PMVP - TradingView

Thu, 28 Dec 2023
Ladenburg Thalmann starts PMV Pharmaceuticals at buy (NASDAQ:PMVP) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 51 (M)
Shares Float 41 (M)
Held by Insiders 2.6 (%)
Held by Institutions 92.5 (%)
Shares Short 2,240 (K)
Shares Short P.Month 2,550 (K)
Stock Financials
EPS -1.33
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.13
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -19.5 %
Return on Equity (ttm) -29.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.46
Qtrly Earnings Growth 0 %
Operating Cash Flow -57 (M)
Levered Free Cash Flow -35 (M)
Stock Valuations
PE Ratio -1.22
PEG Ratio -0.1
Price to Book value 0.38
Price to Sales 0
Price to Cash Flow -1.46
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android